Clinical Trial

CS-206 in Patients With Sickle Cell Disease

Name: CS-206 in Patients With Sickle Cell Disease — clinical trial record (NCT06565026)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2024-08-19; most recent amendment 2026-02-08.

Trial Details

NCT Number	NCT06565026
Lead Sponsor	CorrectSequence Therapeutics Co., Ltd Collaborators: First Affiliated Hospital of Guangxi Medical University
Conditions	Sickle Cell Disease
Enrollment	5 participants
Start Date	2024-09-02
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-10